Equities

Hikal Ltd

Hikal Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)386.50
  • Today's Change8.00 / 2.11%
  • Shares traded462.24k
  • 1 Year change+26.31%
  • Beta1.6498
Data delayed at least 15 minutes, as of Sep 20 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Hikal Ltd's revenues fell -11.79% from 20.23bn to 17.85bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 783.82m to 696.02m, a -11.20% decrease.
Gross margin53.06%
Net profit margin3.76%
Operating margin8.49%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Hikal Ltd fell by 140.27m. However, the company earned 1.87bn from its operations for a Cash Flow Margin of 10.46%. In addition the company used 1.74bn on investing activities and also paid 269.98m in financing cash flows.
Cash flow per share15.34
Price/Cash flow per share24.50
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Hikal Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -11.20%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
Div yield(5 year avg)0.88%
Div growth rate (5 year)0.00%
Payout ratio (TTM)10.91%
EPS growth(5 years)-7.55
EPS (TTM) vs
TTM 1 year ago
-27.93
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.